First‑Line and Adjunctive Therapies to Reduce Albuminuria in Diabetes, Hypertension, and CKD

Primary Foundation Therapy

Sodium‑Glucose Co‑Transporter‑2 (SGLT2) Inhibitors

Renin‑Angiotensin System (RAS) Inhibitors (ACE inhibitors or ARBs)

Additional Risk‑Based Therapy

Non‑steroidal Mineralocorticoid Receptor Antagonist (MRA) – Finerenone

Glucagon‑Like Peptide‑1 Receptor Agonists (GLP‑1 RA)

Treatment Algorithms by Albuminuria Severity

Moderately Increased Albuminuria (UACR 30‑299 mg/g)

Severely Increased Albuminuria (UACR ≥ 300 mg/g)

Blood Pressure Management

Critical Monitoring Requirements

Contraindications & Pitfalls

Referral Considerations

Diabetic Albuminuria Management

Introduction to Treatment

• The American Diabetes Association recommends ACE inhibitors or ARBs at maximum tolerated doses as the first-line treatment for patients with diabetes and albuminuria, regardless of whether hypertension is present 5, 6

Treatment Algorithm

• For patients with moderately increased albuminuria (30-299 mg/g), initiate ACE inhibitor or ARB therapy to prevent progression to macroalbuminuria and reduce cardiovascular risk 7, 8, 9
• For patients with severely increased albuminuria (≥300 mg/g), ACE inhibitor or ARB is strongly recommended as first-line therapy, and consider adding an SGLT2 inhibitor for additional renoprotection independent of glycemic control 5, 8, 9

Additional Glucose-Lowering Agents

• SGLT2 inhibitors are recommended for patients with eGFR ≥20 mL/min/1.73 m² and type 2 diabetes to slow CKD progression and reduce heart failure risk 5
• GLP-1 receptor agonists can be considered for cardiovascular risk reduction, and reduce CVD events, hypoglycemia risk, and slow CKD progression 5

Blood Pressure Management

• Aim for a blood pressure target of <130/80 mmHg in patients with diabetes and albuminuria 7, 9
• Multiple drugs are typically required to achieve blood pressure targets, particularly with diabetic kidney disease, and consider adding a thiazide-like diuretic or dihydropyridine calcium channel blocker if ACE inhibitor/ARB alone is insufficient 8, 9

Critical Monitoring Requirements

• Monitor serum creatinine/eGFR and potassium within 7-14 days after initiating ACE inhibitor or ARB, and continue monitoring at least annually thereafter 8, 9
• Continue ACE inhibitor/ARB even as eGFR declines to <30 mL/min/1.73 m² for cardiovascular benefit, but discontinue if kidney function continues to worsen or refractory hyperkalemia develops 8, 9

Important Contraindications and Pitfalls

• Do not combine ACE inhibitor with ARB, as this increases adverse events without added benefit 7, 8, 9
• Do not combine ACE inhibitor or ARB with direct renin inhibitor 9

Glycemic and Lifestyle Optimization

• Optimize glucose control to reduce risk and slow progression of nephropathy, with a target HbA1c individualized but generally <7% 10
• Initiate protein restriction to 0.8 g/kg/day once overt nephropathy develops, and consider further restriction to 0.6 g/kg/day in selected patients as GFR declines 10

Referral Considerations

• Refer to nephrologist when eGFR falls to <60 mL/min/1.73 m² or when difficulties occur managing hypertension or hyperkalemia 10
• Consider referral for uncertainty about kidney disease etiology or advanced disease (eGFR <30) 7

Renin‑Angiotensin System Inhibition as First‑Line Therapy for Chronic Kidney Disease with Albuminuria

Primary Recommendation

• In patients with chronic kidney disease (CKD) and albuminuria ≥ 30 mg/g, initiate an ACE inhibitor or an angiotensin‑receptor blocker (ARB) as first‑line therapy and titrate to the highest approved dose that is tolerated, because these agents uniquely reduce proteinuria beyond blood‑pressure lowering and slow disease progression. 11, 12

Treatment Algorithm

CKD with Albuminuria (with or without diabetes)

• Start an ACE inhibitor or ARB at a standard dose and titrate to the maximum tolerated dose. 11, 12
• If the patient has type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m², add an SGLT2 inhibitor to further reduce CKD progression. 12
• When blood pressure remains ≥ 130/80 mmHg despite optimal RAS inhibition, add a dihydropyridine calcium‑channel blocker (CCB) or a thiazide‑like diuretic. 13, 11
• If albuminuria persists ≥ 30 mg/g despite maximal RAS inhibition and potassium is within normal range, consider adding finerenone (a non‑steroidal mineralocorticoid receptor antagonist). 12

CKD without Albuminuria

• ACE inhibitor or ARB may still be reasonable as first‑line therapy, although supporting evidence is less robust. 11
• Calcium‑channel blockers or diuretics can be used as first‑line alternatives in this population. 13, 11

Kidney‑Transplant Recipients

• Use a dihydropyridine CCB or an ARB as the first‑line antihypertensive agent (ACE inhibitors are not preferred). 11

Monitoring Requirements

• Measure serum creatinine, eGFR, and potassium 2–4 weeks after initiating or up‑titrating an ACE inhibitor or ARB. 11, 12
• Continue the drug if serum creatinine rises ≤ 30 % within the first 4 weeks, as this reflects the expected hemodynamic effect of reduced intraglomerular pressure. 11, 12
• Reduce dose or discontinue the drug only if:

Blood‑Pressure Targets

• Aim for a blood‑pressure goal < 130/80 mmHg in most CKD patients (or < 140/80 mmHg in elderly individuals). 13, 11, 14

Hyperkalemia Management (without stopping RAS inhibitors)

• Manage elevated potassium with non‑pharmacologic and pharmacologic measures rather than discontinuing ACE inhibitors or ARBs. 11, 12

Contraindications & Pregnancy

• Do not combine two RAS inhibitors (e.g., ACE inhibitor + ARB or any direct renin inhibitor) because this raises the risk of hyperkalemia, acute kidney injury, and hypotension without added benefit. 11
• Discontinue ACE inhibitors or ARBs in women who are planning pregnancy or become pregnant due to teratogenic risk. 12

Adjunctive Renoprotective Agents

• SGLT2 inhibitors lower the risk of CKD progression by approximately 40 % and should be started in patients with type 2 diabetes when eGFR ≥ 20 mL/min/1.73 m². 12
• Finerenone (non‑steroidal mineralocorticoid receptor antagonist) further reduces albuminuria and slows CKD progression when added to optimal RAS inhibition in patients with persistent albuminuria ≥ 30 mg/g. 12
• GLP‑1 receptor agonists provide cardiovascular benefit and modest renal protection in type 2 diabetes. 12

Stepwise Multi‑Agent Regimen for Most CKD Patients

Renoprotective and Cardiovascular Management in Elderly Patients with Diabetic Kidney Disease

Hematologic Assessment

• In elderly patients with diabetes and early chronic kidney disease, a normal complete blood count without anemia indicates the absence of advanced CKD‑related complications. 15

Evidence‑Based Pharmacologic Therapy

SGLT2 Inhibitors

• In patients with an estimated glomerular filtration rate ≥ 20 mL/min/1.73 m², SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin) reduce the risk of chronic‑kidney‑disease progression by approximately 40 %, cardiovascular death by 38 %, and hospitalization for heart failure by 35 %. (Evidence from large randomized trials) 16
• The same agents provide a modest reduction in glycated hemoglobin of about 0.5–0.7 % when added to existing diabetes therapy. (Trial data) 16
• Use of SGLT2 inhibitors is associated with a 5–10 % incidence of genital mycotic infections; patients should be counseled on hygiene and early symptom reporting. (Observational data) 16
• Adequate hydration should be ensured, particularly when a loop diuretic is co‑prescribed for COPD‑related fluid retention, to minimize the risk of volume depletion. (Safety monitoring guidance) 16

GLP‑1 Receptor Agonists

• Adding a GLP‑1 receptor agonist (e.g., liraglutide, semaglutide, dulaglutide) to the regimen of elderly patients with type 2 diabetes and established coronary atherosclerosis lowers the incidence of major adverse cardiovascular events by 12–26 % compared with standard care. (Randomized controlled trial evidence) 16

Antiplatelet Therapy

• Low‑dose aspirin (75–100 mg daily) is recommended for secondary prevention in patients with known coronary artery disease, provided there are no contraindications such as high bleeding risk. (Guideline‑based recommendation) 16

Monitoring and Safety

• Routine monitoring for genital infections, renal function, and volume status is essential when initiating SGLT2 inhibitors in this population. (Safety protocol) 16

COPD‑Related Benefits

• Both SGLT2 inhibitors and GLP‑1 receptor agonists have been shown to reduce the frequency of COPD exacerbations in patients with type 2 diabetes, offering added respiratory benefit beyond cardiorenal protection. (Clinical outcome data) 16
• Annual influenza and pneumococcal vaccinations are advised to lower the risk of respiratory infections that could destabilize COPD and cardiovascular disease. (Preventive health recommendation) 16